Applied Nursing Research
Volume 16, Issue 1 , Pages 22-28, February 2003

Women's feedback on a chemopreventive trial for cervical dysplasia☆☆☆

Mary E. Bieniasz, RN, CS, Diana Underwood, MS, RNC, Joanne Bailey, RN, BSN, Mack T. Ruffin IV, MD, MPH, Department of Family Medicine, University of Michigan, Ann Arbor, MI

Article Outline

Abstract 

This study identifies the risks, benefits, and social influences affecting the decision to participate in a chemoprevention trial for cervical dysplasia. Women from three clinical sites in southeastern Michigan were invited to participate in a semi-structured interview. In previous studies, minority women have significant barriers to participation in clinical trials. However, in this study, women (63% black, 26% white, and 9% other ethnicity), were interested in participating and reported only moderate barriers. These barriers could easily be addressed with resources available to investigators. Copyright 2003, Elsevier Science (USA). All rights reserved.

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Bujorian S. Clinical trials: Issues in the decision-making process. Nursing Forum. 1988;15:779–783
  2. Cassileth BE, Lusk EJ, Miller DS, Hurwitz S. Attitudes toward clinical trials among patients and the public. JAMA. 1982;248:968–970
  3. Cunny KA, Miller HW. Participation in clinical drug studies: motivations and barriers. Clinical Therapeutics. 1994;16(2):273–282 discussion 271-272
  4. Fitzgibbon ML, Prewitt TE, Blackman LR, Simon P, Luke A, Keys LC, et al. Quantitative assessment of recruitment efforts for prevention trials in two diverse black populations. Preventive Medicine. 1998;27(6):838–845
  5. Harris Y, Gorelick P, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. Journal of the National Medical Association. 1996;88(10):630–634
  6. Johansen M, Mayer D, Hoover HC. Obstacles to implementing cancer clinical trials. Seminars in Oncology Nursing. 1991;7(4):260–267
  7. Joseph R. Viewpoints and concerns of a clinical trial participant. Cancer. 1994;74(suppl):2692–2693
  8. Mouton C, Harris S, Rovi S, Solorzano P, Johnson MS. Barriers to black women's participation in cancer clinical trials. Journal of the National Medical Association. 1997;89(11):721–727
  9. Nealon E, Blumberg B, Brown B. What do patients know about clinical trials?. American Journal of Nursing. 1985;85:807–810
  10. Rimer BK. Participant enrollment, participation, and compliance in chemoprevention trials. [Review] [45 refs]. Advances in Experimental Medicine & Biology. 1992;320:111–117
  11. Roberson N. Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer. 1994;74(suppl):2687–2691
  12. Schain W. Barriers to clinical trials. Part II: Knowledge and attitudes of potential participants. [Review] [16 refs]. Cancer. 1994;74(suppl):2666–2671
  13. Swanson M, Ward A. Recruiting minorities into clinical trials: toward a participant-friendly system. Journal of the National Cancer Institute. 1995;87(23):1747–1759
  14. Tangrea JA. Patient participation and compliance in cancer chemoprevention trials: Issues and concerns. [Review]. Proceedings of the Society for Experimental Biology & Medicine. 1997;216(2):260–265
  15. van Gelderen CE, Savelkoul TJ, van Dokkum W, Mevlenbelt J. Motives and perception of healthy volunteers who participate in experiments. European Journal of Clinical Pharmacology. 1993;45(1):15–21

☆ Supported in part by the National Cancer Institute grants CA68291 and CA80846.

☆☆ Address reprint requests to Mack T. Ruffin IV, MD, MPH, Department of Family Medicine, University of Michigan, 1018 Fuller Street, Ann Arbor, MI 48109-0708.

PII: S0897-1897(02)10901-3

doi:10.1053/apnr.2003.016022

Applied Nursing Research
Volume 16, Issue 1 , Pages 22-28, February 2003

Article Tools